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ABSTRACT: Glycoprotein gp120 is a surface antigen and virulence factor of human
immunodeﬁciency virus 1. Broadly neutralizing antibodies (bNAbs) that react to gp120 from
a variety of HIV isolates oﬀer hope for the development of broadly eﬀective immunogens for
vaccination purposes, if the interactions between gp120 and bNAbs can be understood. From
a structural perspective, gp120 is a particularly diﬃcult system because of its size, the presence
of multiple ﬂexible regions, and the large amount of glycosylation, all of which are important
in gp120−bNAb interactions. Here, the interaction of full-length, glycosylated gp120 with
bNAb b12 is probed using high-resolution hydroxyl radical protein footprinting (HR-HRPF)
by fast photochemical oxidation of proteins. HR-HRPF allows for the measurement of
changes in the average solvent accessible surface area of multiple amino acids without the
need for measures that might alter the protein conformation, such as mutagenesis. HR-HRPF
of the gp120−b12 complex coupled with computational modeling shows a novel extensive
interaction of the V1/V2 domain, probably with the light chain of b12. Our data also reveal
HR-HRPF protection in the C3 domain caused by interaction of the N330 glycan with the b12 light chain. In addition to
providing information about the interactions of full-length, glycosylated gp120 with b12, this work serves as a template for the
structural interrogation of full-length glycosylated gp120 with other bNAbs to better characterize the interactions that drive the
broad speciﬁcity of the bNAb.
The human immunodeﬁciency virus 1 (HIV-1) gp120envelope glycoprotein is the major target of neutralizing
antibodies.1,2 The gp120 molecule consists of a polypeptide
core of roughly 60 kDa. Extensive modiﬁcation by N-linked
glycosylation increases the molecular weight of the molecule to
∼120 kDa.3 The amino acid sequence of gp120 is composed of
ﬁve conserved regions (C1−C5) and ﬁve variable regions (V1−
V5), many of which are highly ﬂexible. The majority of
antibodies raised against gp120 have very narrow ranges of
eﬀectiveness and are eventually evaded by the virus. However, a
subset of raised antibodies have been found to be eﬀective
against a broader array of isolates. The development of a
vaccine immunogen that elicits these broadly neutralizing
antibodies (bNAbs) and confers protective immunity remains a
challenge. Improved knowledge of the Env structure and what
constitutes a full neutralization epitope will aid in rational
immunogen design to elicit potent bNAbs. However, gp120 is a
very challenging molecule for structural biology. The extensive
glycosylation, diversity of isoforms, and broad conformational
ﬂexibility of gp120 pose formidable barriers for crystallization.
To surmount these diﬃculties and construct a crystal structure
of gp120, sources of likely conformational heterogeneity such
as N-linked carbohydrates, ﬂexible or mobile N- and C-termini,
and variable internal loops (like V1/V2 and/or V3) are often
reduced or eliminated, and ligands such as CD4 are used to
restrict conformational mobility and to alter the crystallization
surface.4−12 These stabilized structures provide valuable
information at high resolution, but at the cost of eliminating
regions that have been shown to be important for many
gp120−antibody interactions.13
The ﬁrst broadly neutralizing human monoclonal antibody
(mAb), b12, was isolated from clade B-infected patients and
binds to gp120 at and near its CD4 binding site (CD4bs).7,10,14
Binding of b12 to the surface of gp120 blocks attachment of
CD4 and thus prevents the entry of HIV-1 into a target cell.7,10
Therefore, gp120 appears to present the b12 epitope in
conjunction with several other weakly neutralizing and
overlapping epitopes. However, while several other CD4bs
antibodies with potency and breadth greater than those of b12
have been discovered since then, b12 remains a valuable model
for anti-CD4bs bNAbs because of its history of experimental
study.15−17 A crystal structure of b12 in complex with a
truncated, deglycosylated, and mutationally stabilized gp120
core [Protein Data Bank (PDB) entry 2NY7] has revealed that
the contacts between b12 and gp120 are centered around the
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CD4 binding loop spanning residues 364−373 but involves
many other residues.10 The truncated, deglycosylated, and
mutationally stabilized gp120 core is diﬀerent from its mature
counterpart in important ways, including a fully truncated V1/
V2 domain. It was found that the removal of V1/V2 loops
signiﬁcantly weakens the binding of b12 to gp120.17 The
removal of a single N-linked glycosylation site at the V3 loop
increased the neutralization sensitivity of CD4bs antibodies.18
Because of their absence in the crystal structure of the gp120
core in complex with b12, it remains unclear how the V1/V2
and V3 loops interact with b12. The characterization of the
contact sites between mature gp120 and b12 will provide a
better understanding of the speciﬁc broadly neutralizing activity
of b12 against gp120. As there is no crystal structure available of
an intact, glycosylated gp120 in complex with b12, molecular
modeling has been used to predict the interface between b12
and the gp120 core in the truncated area by using available
crystal structures as the basis for homology modeling.5,7,19
However, such molecular modeling has limitations in terms of
accuracy and reliability and should ideally be coupled with
experimental testing and constraints.20
In this study, we used high-resolution hydroxyl radical
protein footprinting (HR-HRPF) by fast photochemical
oxidation of proteins (FPOP) coupled with mass spectrometry
(MS) to characterize the binding interface between mature
HIV-1 JR-FL gp120 and b12. Hydroxyl radical protein
footprinting is a relatively new method for probing changes
in the topography of a protein. The measured rate of the
reaction of hydroxyl radicals at any particular amino acid side
chain depends primarily upon two factors: the chemical
reactivity of the side chain (which is invariant between
conformations) and the accessibility of the side chain to the
radical. Therefore, by monitoring changes in the HR-HRPF
reactivity, we can determine changes in the average solvent
accessibility caused by changes in conformation and/or
dynamics or direct shielding by protein−protein or protein−
ligand binding. MS-based hydroxyl radical protein footprinting
has shown great promise in the measurement of protein
conformational changes, protein−protein interactions, and
protein−ligand binding events.21−27 HR-HRPF by certain
techniques, including FPOP28 and electron accelerator
radiolysis,29 stably modiﬁes solvent accessible amino acid side
chains without deforming the protein structure during the time
scale of modiﬁcation, allowing for heavy surface labeling of the
native structure.
To measure changes in HR-HRPF reactivity, the stable
modiﬁcations to the protein side chains are analyzed by liquid
chromatography and mass spectrometry (LC−MS), relatively
quantifying modiﬁed and unmodiﬁed peptides, and the MS
signal of the oxidized version(s) of each peptide is compared to
the MS signal of the unoxidized version of the same peptide to
quantify oxidation at the peptide level. Via measurement of the
rate of reaction of each amino acid side chain of a protein under
two diﬀerent structural conditions (in this case, b12-bound vs
free gp120), relative changes in the accessibility of each amino
acid can be measured.25 Previous work from our group has
shown that, using ETD-based methods for quantifying multiple
adjacent sites of isomeric oxidation products, we can accurately
quantify changes in the hydroxyl radical footprint down to
single-amino acid spatial resolution,30,31 providing structural
information with higher spatial resolution and more accuracy.
This method oﬀers an important alternative method for
characterizing protein−protein and protein−ligand interactions
in cases in which it is not possible to determine high-resolution
three-dimensional structures of complexes because of the
heterogeneity, ﬂexibility, and/or size of the target(s).
A glycosylated, full-length homology model of JR-FL gp120
was constructed, and a 500 ns molecular dynamics simulation
was performed. The resulting simulation was aligned to the
available structure of gp120 HXBc2 in complex with b12,
allowing an estimation of the contact area between b12 and
glycosylated JR-FL. This provided a structure-based ration-
alization of the experimentally determined protection sites as
well as detailed insights into the regions of JR-FL aﬀected by
complexation with b12.
■ MATERIALS AND METHODS
Materials and Reagents. Hydrogen peroxide (30%) was
purchased from J. T. Baker (Phillipsburg, NJ). Dithiothreitol
(DTT) and high-performance liquid chromatography-grade
acetonitrile were purchased from Fisher Scientiﬁc (Fair Lawn,
NJ). Methionine amide was purchased from Bachem
(Torrance, CA). Catalase, adenine, formic acid, L-glutamine,
and phosphate-buﬀered saline (PBS) were obtained from
Sigma-Aldrich Corp. (St. Louis, MO). Sequencing-grade
modiﬁed trypsin and Glu-C were purchased from Promega
Corp. (Madison, WI). PNGase F (500000 units/mL) was
purchased from New England Biolabs (Ipswich, MA). All
reagents were used without further puriﬁcation. Puriﬁed water
(18 MΩ) was obtained from an in-house Milli-Q Synthesis
system (Millipore, Billerica, MA).
Construction, Expression, and Puriﬁcation of gp120
and Human mAbs IgG1 b12. Recombinant HIV-1 gp120
protein vaccine was produced from gp120-JR-FL DNA vaccine-
transfected 293F cells. Codon-optimized gp120-JR-FL DNA
vaccine was constructed in the pJW4303 DNA vaccine vector as
previously reported.32 Seventy-two hours after the transient
transfection of 293F cells, the culture supernatant was
harvested and the secreted gp120 protein puriﬁed using a
lectin column. The puriﬁed gp120 protein was veriﬁed and
analyzed by sodium dodecyl sulfate−polyacrylamide gel
electrophoresis and Western blot analysis (data not shown).
Monoclonal antibody (mAb) IgG1 b12, speciﬁc for the gp120
CD4 binding site (CD4bs), was purchased from Polymun
Scientiﬁc (Klosterneuburg, Austria).
HR-HRPF by FPOP. Six microliters of gp120 JR-FL (25
μM) was incubated with 6 μL of PBS either with or without 25
μM b12 at 37 °C for 1 h. HR-HRPF by FPOP was then
performed in triplicate as previously described. Brieﬂy, 4 μL of
glutamine (100 mM) and 2 μL of adenine (200 μg/mL) were
mixed with 12 μL of gp120 alone or the gp120−b12 reaction
solution. Adenine was added as a radical dosimeter to monitor
the available radical dose in each sample. Two microliters of 3%
hydrogen peroxide (1 M, freshly prepared) was added to the
mixture immediately prior to irradiation. FPOP labeling of the
total volume of a 20 μL mixture was immediately performed.
The KrF excimer laser power (GAM Laser Inc., Orlando, FL)
was adjusted to 75 mJ/pulse and its pulse frequency set to 5
Hz. The ﬂow rate was set to 12.19 μL/min to ensure a 10%
exclusion volume to prevent repeat hydroxyl radical exposure.28
Each replicate was collected in a microcentrifuge tube
containing a quench mixture of 10 μL of 140 mM H-Met-
NH2 and 10 μL of 2 μM catalase to eliminate secondary
oxidants such as remaining hydrogen peroxide, protein
peroxides, superoxide, etc. The samples were incubated in the
quench solution for 30 min at room temperature with pipet
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mixing. Control samples were handled in the same manner as
those submitted to FPOP, but they were not laser irradiated;
instead, they were incubated for 2 min with H2O2, after which
the solution was added to the collection solution containing
catalase and H-Met-NH2. All experiments were performed in
triplicate for statistical analysis.
Following irradiation, 2 μL of the sample (40 μL) was
analyzed to assess the oxidation of adenine after HR-HRPF by
UV at 260 nm (Thermo Scientiﬁc NanoDrop 2000c UV−vis
spectrophotometer) to ensure comparable amounts of available
hydroxyl radical for oxidizing the analyte, as previously
reported.33 The amounts of adenine oxidation are similar
among all tested samples with an average of around 53%
oxidized adenine and a CV of <5% (data not shown), which
indicates the same level of hydroxyl radical available among all
samples.
The lyophilized powder was resuspended in 50 μL of 100
mM ammonium bicarbonate buﬀer. DTT (10 μL, 50 mM) was
added and incubated at 65 °C for 30 min to denature and
reduce the protein. After the mixture had been cooled to room
temperature, a 1:20 Glu-C:protein weight ratio was added to
the protein sample and the mixture incubated at room
temperature for 2 h. Glu-C was deactivated by heating the
sample to 95 °C for 10 min; then after the samples had been
cooled to room temperature, a 1:20 trypsin weight ratio was
added to the samples for overnight digestion at 37 °C while the
sample was being rotated. Digestion was terminated by adding
12 μL of DTT (50 mM) and heating the samples to 95 °C for
10 min. Finally, when the samples were cooled to room
temperature, 150 units of PNGase F was added to the digested
samples and the samples were incubated at 37 °C for 16 h. The
reaction was terminated by adding 12 μL of DTT (50 mM) and
heating the sample to 95 °C for 10 min. Samples were stored at
−20 °C until nanoLC−MS/MS analysis.
HR-HRPF samples were analyzed on an LTQ Orbitrap XL
instrument (Thermo Fisher Scientiﬁc) controlled with Xcalibur
version 2.0.7 (Thermo Fisher, San Jose, CA). Samples were
loaded on a 10 cm column with a PicoFrit tip, bomb-packed
with C18 reverse phase material (Magic, 0.075 mm × 100 mm,
5 μm, 300 Å, Michrom, Auburn, CA). Chromatography was
performed using mobile phase A (0.1% formic acid in water)
and mobile phase B (0.1% formic acid in 80% acetonitrile) with
a 160 min gradient consisting of 0 to 60% solvent B over 60
min at a rate of 135 μL/min, ramped to 100% B over 20 min,
held for 9 min, and then returned to 0% B over 1 min and held
for 70 min. Peptides were eluted directly into the nanospray
source of an LTQ Orbitrap XL instrument using the bomb-
packed column as the nanospray emitter. All data were acquired
in positive ion mode. CID (collision-induced dissociation) and/
or ETD (electron transfer dissociation) was used to fragment
peptides. The spray voltage was set to 2.0 kV, and the
temperature of the heated capillary was set to 200 °C. In CID
mode, full MS scans were acquired from m/z 400 to 1500
followed by eight subsequent MS2 scans on the top eight most
abundant peptide ions. In ETD mode, the parent ions of all
identiﬁed peptides under CID mode were listed in the parent
ion mass list. ETD-based precursor activation was performed
for 100 ms, including charge state-dependent with supplemen-
tal activation enabled. Precursor ions were isolated with width
of 3 m/z units.
HR-HRPF Data Analysis. Unoxidized gp120 controls,
oxidized gp120, and oxidized gp120−b12 complex peptide
sequences were initially identiﬁed using ByOnic version 1.2-250
(Protein Metrics). The enzyme was deﬁned to cleave the
protein after lysine, arginine, asparatic acid, and glutamine.
Deamination on both asparagine and glutamine and all possible
major oxidation modiﬁcations25 were included as variable
modiﬁcations for database searches. All tandem mass spectral
assignments and sites of oxidation were veriﬁed manually via
the peptide modiﬁcation complexity. The LC−MS peak
intensities of the digested peptides and corresponding oxidation
products were used to calculate the average oxidation events
per peptide in the sample. Peptide level quantitation is
calculated by summing the ion intensities of all the oxidized
peptides multiplied by the number of oxidation events required
for the mass shift (e.g., one event for +16, two events for +32)
and then divided by the sum of the ion intensities of all
unoxidized and oxidized peptide masses (eq 1):
= + × + + ×
+ + × + + +
+ + + + +
P I I
I I I
I I
[ ( 16) 1 ( 32) 2
( 48) 3 ...]/[ ( 16)
( 32) ( 48) ...]
oxidized oxidized
oxidized unoxidized oxidized
oxidized oxidized (1)
where P denotes the oxidation events at the peptide level and I
values are the peak intensities of oxidized and unoxidized
peptides.
gp120 control samples unilluminated by the UV laser, but
otherwise identical to the experimental samples, were analyzed
to ensure that background oxidation would not be intense
enough to interfere with HR-HRPF data. Illumination-free
controls showed <10% of the oxidation extent of the gp120
sample with UV laser for peptides 19−31, 37−63, 64−69, 178−
197, 261−274, 386−396, and 397−404 (data not shown). The
small amount of oxidation happening occurred at M or C
because of the sample preparation process (especially for
residue M), protein expression, and puriﬁcation. The
interference of this background is not signiﬁcant enough to
aﬀect the comparison of the oxidation extent between gp120
and gp120−b12 samples and was subtracted from experimental
samples.
In cases in which oxidation at speciﬁc sites can be identiﬁed
on the basis of either the mass diﬀerences between nonisomeric
oxidation products or the presence of only a single oxidation
site within a peptide, residue level quantitation is calculated
from the LC−MS signal intensities of each peptide containing a
speciﬁc oxidized amino acid (Ioxidized), relative to the total of all
intensities associated with that peptide sequence (Ioxidized +
Iunoxidized) using the following straightforward relationship:
24
= ∑
∑ + ∑
i
I
I I
oxidation/residue oxidized
oxidized unoxidized (2)
In cases in which the peptide isomers are oxidized at multiple
adjacent sites in a single sequence that results in an identical
mass shift, residue level quantitation is calculated from the
fragment ion intensities from ETD to determine the oxidation
extent at a speciﬁc residue site based on our previous
studies.30,31 Brieﬂy, an oxidized peptide with multiple sites of
oxidation can generate both oxidized and unoxidized sequence
ions in its tandem mass spectrum. The fractional oxidation of a
given sequence ion is deﬁned as the ratio between the oxidized
sequence ion intensity and the sum of the intensity of the
corresponding oxidized and unoxidized sequence ion (eq 3).
=
+
f C
I C
I C I C
( )
( )
( ) ( )i
i
i i
oxidized
unoxidized oxidized (3)
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where f(Ci) denotes the fractional oxidization of sequence ion i
(e.g., oxidized C3 ions generated by ETD) and I(Ci) denotes
the intensity of sequence ion i, whether it is the oxidized or
unoxidized form. The absolute level of oxidation for a given
amino acid residue i is based on both the average oxidation
event of the peptide and the fractional oxidation of the
corresponding sequence ions, as shown in eq 4:
= − −i P f C f Coxidation/residue [ ( ) ( )]i i 1 (4)
where P is the average oxidation events per peptide as derived
from eq 1 and the term in brackets is the fractional oxidation
diﬀerence of two adjacent sequence ions i and i − 1.
Multiplying the average number of oxidations per peptide by
the fraction of that oxidation that occurs on a given amino acid
residue yields the average oxidation events per residue. In cases
in which ETD did not yield suﬃcient product ions for
quantiﬁcation, CID was used to provide semiquantitative
information about changes in the footprint at a residue level.
The protection by b12 binding is deﬁned as the ratio of the
diﬀerence in oxidation extent between the gp120 sample alone
and the gp120−b12 binding sample to the oxidation extent of
the gp120 sample alone, as shown in eq 5:
=
− ×−
(
) ( )
i
i i
% protection oxidation/residue
oxidation/residue / oxidation/residue 100
gp120
gp120 b12 gp120
(5)
Glycosylation Analysis. An aliquot of each sample was
denatured by being incubated with 10 mM dithiothreitol at 56
°C for 1 h and alkylated with 55 mM iodoacetamide for 45 min
in the dark prior to digestion with proteases optimized on the
basis of the amino acid sequence of each target protein.
Following digestion, the samples were deglycosylated by
PNGaseF in the presence of H2
18O that coverts Asn residues
carrying N-linked glycans to [18O]Asp residues. The resulting
peptides were separated on a 75 μm (inside diameter) × 15 cm
C18 capillary column (packed in house, YMC GEL ODS-
AQ120 ÅS-5, Waters) and eluted into the nanoelectrospray ion
source of an Orbitrap Fusion Tribrid mass spectrometer
(Thermo Fisher Scientiﬁc) with a 180 min linear gradient
consisting of 0.5 to 100% solvent B over 150 min at a ﬂow rate
of 200 nL/min. The spray voltage was set to 2.2 kV, and the
temperature of the heated capillary was set to 280 °C. Full MS
scans were acquired from m/z 300 to 2000 at 120K resolution,
and MS2 scans following collision-induced fragmentation were
collected in the ion trap for the most intense ions in the Top-
Speed mode within a 3 s cycle using Fusion instrument
software (version 1.1, Thermo Fisher Scientiﬁc). The resulting
spectra were analyzed using SEQUEST (Proteome Discoverer
1.4, Thermo Fisher Scientiﬁc) with a full MS peptide tolerance
of 20 ppm and a MS2 peptide fragment tolerance of 0.5 Da and
ﬁltered using ProteoIQ (version 2.7, Premier Biosoft) at the
protein level to generate a 1% false discovery rate for protein
assignments. Site occupancy was calculated using spectral
counts of [18O]Asp peptides to the identical peptide containing
Asn. The sole exception is N88, which was wholly unobserved
as glycosylated or nonglycosylated by this method. Glyco-
sylation of this site was assigned on the basis of the high
abundance of the N→ D substitution of this site after PNGase
F treatment during HR-HRPF data acquisition and analysis, as
detailed above.
A site was assigned as occupied for the purpose of modeling
if the site was predominantly glycosylated across all peptides in
which the site was observed. Notably, sites N241 and N262 co-
reside on a single peptide and were detected as individually
glycosylated 56% of the time, but simultaneous glycosylation
was detected for only 6% of observed peptides. Thus, the
predominant state was for only one site to be glycosylated.
Given their equal rate of occupancy, we arbitrarily chose N241
for glycosylation in the model.
Model Building. Blastp34 was used to ﬁnd three-dimen-
sional (3D) structures from the PDB with sequences similar to
that of JR-FL. A modiﬁed JR-FL has been crystallized
previously (PDB entry 2B4C); however, the N- and C-termini
were truncated, and the V1/V2 region was substituted with a
GAG tripeptide. The model used here is based on 2B4C and
employs additional crystal structures (PDB entries 4NCO,
3JWD, 4HPO, 4R4H, 4TVP, and 9B4C) to model a complete
JR-FL. Modeler35 incorporated each of these structures (see
alignments in Figure S1) to generate ﬁve models of complete
gp120.
Model Glycosylation. Previous work revealed that
expression of gp120 from Ba-L (a clade B isolate) in 293F
cells resulted in a mixture of a complex and high-mannose
glycans and that the level of interaction of the B clade gp120
with the b12 bNAb was increased by expression in cells that
increased the level of high-mannose glycosylation.36 Because
the full diversity of possible glycan structures is impractical to
simulate even for individual compositions of complex glycans,
Man9GlcNAc2 structures were modeled into all sites assigned as
glycosylated, as this glycan is a single, biologically relevant
structure that explores the extended reach of glycans in
examining both glycan−antibody interactions and glycan
shielding of the antibody binding surface. GLYCAM-Web
(www.glycam.org) was used to generate 3D structures of the
common rotamers of Man9GlcNAc2. These structures were
superimposed onto the Asn side chain at each assigned
glycosylation site. The glycan structure was adapted to the local
protein environment and any previous glycans in the following
manner: the four most populated conformations of N-linked
Asn side chains found in the PDB were assessed in series by
altering the χ, ϕ, and ψ angles of the N-linked glycan. Any van
der Waals (vdW) overlaps between the glycan and the
glycoprotein were minimized by altering the torsion angles of
the Asn-GlcNAc and interglycosidic linkages by ±20° in 5°
increments. The ﬁrst glycan rotamer and Asn side chain
conformer that allowed the glycan to ﬁt without large vdW
overlaps was added to the glycoprotein structure.
Model Selection. A single model of JR-FL was chosen on
the basis of the number of experimentally determined
glycosylation sites that were accessible for glycosylation and
the DOPE score provided by Modeler. A recent crystal
structure of a complete JR-FL (PDB entry 5FYK),37 released
during the preparation of this work, allowed validation of the
model generated here. A Needleman−Wunsch alignment using
a BLOSUM-62 matrix38 gave a relatively large root-mean-
square deviation (RMSD) of 5.2 Å over 450 atom pairs.
However, most of the deviation is in the ﬂexible N- and C-
terminal domains that are ordered by the presence of gp41 in
the crystal structure. When these regions are discounted, the
RMSD drops to 1.0 Å over 303 atom pairs, indicating that the
homology model successfully predicted the remaining 3D
structure.
Molecular Dynamics Simulation. All simulations were
performed with the CUDA implementation of PMEMD39,40 in
the Amber14 software suite.41 The carbohydrate was modeled
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using the GLYCAM06j-1 force ﬁeld,42 while the Amber ﬀ14SB
force ﬁeld43 was employed for the protein. A Berendsen
barostat with a time constant of 1 ps was employed for pressure
regulation, while a Langevin thermostat with a collision
frequency of 2 ps−1 was employed for temperature regulation.
A nonbonded interaction cutoﬀ of 8 Å was employed. Long-
range electrostatics were treated with the particle mesh Ewald
(PME) method.44 Covalent bonds involving hydrogen were
constrained with the SHAKE algorithm allowing a time step of
2 fs.45
Each system was placed in a cubic box of TIP5P water46 with
an 8 Å buﬀer between the solute and the periodic boundary.
Five sodium ions were added to neutralize the overall charge.
Energy minimization was performed for 20000 steps (10000
steepest decent, followed by 10000 conjugant gradient) with
Cartesian restraints (5 kcal mol−1 Å−2) on solute heavy atoms.
This was followed by a 400 ps solvent equilibration phase at
300 K under nPT conditions. Cartesian restraints (5 kcal mol−1
Å−2) were employed on the Cα atoms of the ﬁrst and last three
residues (N- and C-terminal) during a 1 ns structural
equilibration phase and 500 ns production phase (nPT).
Structure of gp120 (JR-FL) in Complex with the b12
Antibody. A structure-based sequence alignment of gp120
(HXBc2) in complex with the b12 Ab (PDB entry 2NY7) with
100 snapshots from the MD simulation of JR-FL was
performed using Sequoia,47 with an RMSD of 4.14 Å for 245
equivalent matches based on alignment with the original model,
with a Sequoia alignment score of 0.08. On the basis of each
alignment, an estimation of the contact area between b12 and
JR-FL was obtained by averaging the percentage change in the
respective solvent accessibilities48 for each snapshot in the
presence and absence of the b12 structure.
Figure 1. Sequence of HIV-1 gp120 (JR-FL). The sequences covered by HR-HRPF experiments are overlined with green. The identiﬁed oxidation
sites are shown in red text with protected sites underlined and the sole exposed site in italics. The heavily occupied N-linked glycosylation sites are
shown in green text. The variable domains are labeled above the sequence.
Figure 2. Peptide level HRPF of gp120 footprinting for gp120 alone (white) and the gp120−b12 complex (gray) (mean ± standard deviation; n =
3). Peptides highlighted with a red star showed a statistically signiﬁcant change in oxidation extent upon gp120−b12 binding (α ≤ 0.05).
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■ RESULTS
Glycosylation Analysis of gp120 and the gp120−b12
Complex. The recombinant glycoprotein gp120 used in this
study was expressed as a 477-amino acid mature protein
containing intact N- and C-termini, ﬁve variable regions (V1/
V2, V3, V4, and V5) and ﬁve conserved regions (C1−C5).
Following Glu-C and trypsin digests of gp120, 32 unique
peptides were identiﬁed by CID-based MS/MS data, covering
72% of the overall sequence. Eighteen highly occupied N-linked
glycosylation sites were identiﬁed. The details of the oxidation
sites and glycosylation sites are listed in Figure 1.
HR-HRPF of the gp120−b12 Complex. Twenty-nine
peptides were seen to be modiﬁed by FPOP footprinting. Sixty-
one oxidized residues were identiﬁed in these modiﬁed peptides
on the basis of a Byonic database search and veriﬁed manually
from the CID and/or ETD MS/MS spectra. Almost one in ﬁve
residues in the peptides detected was modiﬁed, indicating a
high yield of protein labeling through the short FPOP reaction
window. The oxidation extent of the 29 modiﬁed peptides was
determined at the peptide level by measuring the intensity of
the oxidized peptide ion compared to the sum of oxidized and
unoxidized peptide ions as calculated by eq 1. The side-by-side
comparison of the oxidation extent of sequenced peptides in
gp120 and gp120−b12 samples is shown in Figure 2. The
overall number of average oxidations per peptide for diﬀerent
peptides varies signiﬁcantly from 0.003 for peptide 179−192 to
3 for peptide 198−207. Most peptides show comparable
amounts of oxidation between binding and nonbinding
samples. Eleven peptides, including 92−97, 98−106, 156−
168, 173−178, 179−192, 316−327, 336−343, 358−370, 410−
419, 433−440, and 467−476, showed a signiﬁcant decrease in
oxidation extent upon b12 binding, indicating a structural event
that shielded the sites from the radical.
To investigate structural changes upon binding between
gp120 and b12 at a high spatial resolution, the CID- and ETD-
Figure 3. ETD spectrum of peptide 143-YALFYK-148 and its oxidation products. (A) Unoxidized peptide 173-YALFYK-178. (B) Mixture of singly
oxidized isomers. By measuring the ratio of oxidized product ions to total product ions for each fragment, oxidation can be quantiﬁed to occur on
F176 and the Y173-A174 fragment (on the basis of CID data and the relative reactivities of alanine and tyrosine, almost no oxidation occurs on
A174).
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based tandem mass spectra of these 11 peptides were analyzed.
A representative ETD spectrum is shown in Figure 3. On the
basis of the CID/ETD fragmentation ions, most of the 11
peptides were found to have multiple oxidation sites except
peptides 156−168 and 336−343. For peptides with only one
oxidation site, the oxidation extent at the residue level was
calculated by eq 2. For oxidation isomers having multiple
oxidation sites on a single sequence (peptides 143−148, 149−
162, 284−296, 326−338, 375−383, and 397−404), the
oxidation extent at residue level was calculated by eqs 3 and
4. Oxidized residues that exhibit HR-HRPF protection upon
b12 binding are listed in Table 1. Because of the semi-
quantitative nature of CID-based oxidation quantiﬁcation,30
CID-based data were selected only when ETD data were not
available (residues M72, M76, and C127).
It should be noted that the HR-HRPF technique cannot
diﬀerentiate changes in solvent accessibility as a result of direct
binding from those due to conformational or dynamic
perturbations. Therefore, even a preliminary 3D model is
valuable for interpretation of the HR-HRPF data, especially
when dealing with a protein with as many dynamic domains as
full-length, glycosylated gp120. With the exception of the small
V5 domain, we were able to probe at least one amino acid in
each domain by HR-HRPF. Residues that show signiﬁcant
diﬀerences in oxidation due to altered average solvent
accessibility after complex formation can be directly involved
in b12 binding or experiencing conformational and/or dynamic
changes that occur upon b12 binding. Residues that were
oxidized, yet showed no protection upon b12 binding,
experienced no net change in the average solvent accessible
surface area of the side chains probed.
Alignment of b12. The 3D structure of gp120 (HXBc2) in
complex with b12 (PDB entry 2NY7) was aligned with the
gp120 (JR-FL) model generated here. Residues that experi-
enced protection from HR-HRPF oxidation upon b12 binding
are plotted against a full-length model of glycosylated gp120
aligned with the stabilized gp120−b12 complex structure
(RMSD of 2.3 Å) and shown in Figure 4. The alignment
provided an estimation of the direct contact area between b12
and gp120 (JR-FL), and changes in solvent accessibility due to
direct interaction between b12 and gp120 were calculated
(Table 1). During the MD simulation, the V1/V2 region
samples conformations that overlap with the area occupied by a
bound b12, indicating that b12 binding would impact the
ensemble of conformations adopted by the V1/V2 region,
either by inducing new conformations or by just limiting the
available conformational space.
The combination of HR-HRPF data and modeling allows us
to predict which of those residues are directly protected from
oxidation upon complexation (residues D180, V182, P183,
P417, R419, and M426) and which become protected via
induced conformational and/or dynamic changes in the gp120
(JR-FL) structure (residues M95, W96, M100, M104, F176,
C157, Y173, I322a, I323, W338, M434, Y435, V360, F361, and
H363). The combination also allows us to determine residues
at which the model disagrees with the HR-HRPF data,
indicating regions of either insuﬃcient modeling or unreliable
experimental results to be probed by further experimentation
(L179 and I184).
Table 1. Protection of Residues from HR-HRPF upon b12
Binding
residuea
% HR-HRPF protection
upon b12 bindingb
direct protection in MD upon
b12 binding (Δ%)c
M95 31.9 0%
W96 81.8 0%
M100 84.6d 0%
M104 66.0d 0%
C157 100d 64%
Y173, A174 100 53%, 76%
F176 100 70%
D180 64.5 35%
V182, P183 21.3 32%, 54%
I322a 43.6 0%
I323 28.2 14%
W338 100 0%
V360 72.4 0%
F361 73.3 0%
H363 70.4 0%
P417, C418,
R419
45 0%, 0%, 0%
M434 28.5 0%
Y435 28.2 0%
C445 −35.7 0%
M475 11.3 0%
aThe residue numbering used is based on the HXB2 numbering
system. bThe protection upon binding for each residue was calculated
by the changesin oxidation extent between gp120 and the gp120−b12
complex divided by the oxidation extent of gp120. cThe direct
protection is calculated by measuring the change in solvent
accessibility after alignment of b12. The values are averages from the
MD simulation. dCID-based data were used in HR-HRPF results and
should be considered semiquantitative.
Figure 4. Glycosylation and HRPF of gp120. A model of full-length
glycosylated gp120 (ribbon protein in light gray, licorice
Man9GlcNAc2 glycans in dark gray) was generated and relaxed by
MD simulation and then aligned with the crystal structure of stabilized
gp120 bound to the b12 Fab (aligned gp120 not shown, ribbon b12 in
dark gray) (PDB entry 2NY7). Residues that showed protection from
HRPF upon b12 binding are colored red. Residues that showed no
protection from HRPF are colored blue. Residue C445 (also blue)
showed an exposure to HRPF upon b12.
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■ DISCUSSION
The X-ray crystal structure of monomeric gp120 in complex
with the b12 Fab includes only 62% of our intact gp120
polypeptide sequence and does not include glycosylation.10
The structure lacks most of the residues in the V1/V2 loops
(residues 121−203), V3 loop (residues 298−329), V4 loop
(residues 393−404), and portions of the amino and carboxy
termini (residues 31−82 and 493−507, respectively). In this
reported crystal structure, a total of 33 residues were deﬁned as
contact sites. In the current HR-HRPF study, 22 residues were
identiﬁed as being protected from hydroxyl radicals upon b12
binding. It is clear that the V1/V2 loops and V3 loop can aﬀect
binding of the antibody to the CD4bs either by direct contact
or by transmitted conformational eﬀects.49 The deletion of the
V1/V2 and V3 loops also has an adverse eﬀect on the binding
of b12 to gp120.50 The application of a full-length, glycosylated
model of gp120 allows us to probe and try to explain the
observed roles of these and other gp120 domains in b12
binding.
V1/V2 Domain. The V1/V2 domain is highly dynamic and
is excised from the published X-ray crystal structure of gp120
bound to b12 to promote crystallization.10 However, alanine
scanning mutagenesis data have shown that several amino acids
in the V2 region are important for b12 binding.50 Similarly, the
crystal structure shows no direct interaction between the light
chain of the b12 antibody and gp120; however, mutagenesis
found that several amino acids in the L1 and L3 CDR loops
were important for binding of b12 to gp120.51 HR-HRPF
results of the V1/V2 domain within full-length, glycosylated
gp120 are shown in Figure 5, with glycans labeled and shown as
3D SNFG symbols52 positioned at each residue’s ring center.
These results revealed several amino acids that were protected
from HR-HRPF upon b12 binding. C157 and Y173 are two
residues on adjacent strands of an antiparallel β-sheet that both
experience 100% protection from HR-HRPF upon b12 binding.
F176 resides on the C-terminal end of the second strand of that
same β-sheet and also exhibits 100% protection from HR-
HRPF upon b12 binding. F176 and C157 present their side
chains to the opposite face of the β-sheet from Y173 (Figure 5,
inset), suggesting that the protection observed by these
residues is probably not all from direct interaction with the
b12 antibody but rather from stabilization of this β-sheet upon
antibody binding. We also observe modest protection of D180
and V182/P183 upon b12 binding, but neighboring residues
L179, V181, and I184 are not protected upon b12 binding. This
targeted protection is more in line with the eﬀects of direct
interaction, as a change in dynamics or gross conformation is
likely to aﬀect all amino acids in a region.
Modeling of the glycosylated V1/V2 domain into the gp120
structure revealed a potential interaction between the V1/V2
domain and the CDR loops of the b12 light chain, as well as a
loop of the b12 heavy chain. However, both L179 and I184 are
outliers as their oxidation was not aﬀected by b12 binding but
were predicted to be in direct contact with b12. These outliers
are within the ﬂexible V1/V2 region, and the inconsistency with
the footprinting data may be the result of the dynamics of this
region. Previously, alanine scanning mutagenesis was performed
on monomeric gp120 (JR-CSF) to deﬁne in more detail which
residues on gp120 inﬂuence or modulate b12 reactivity. The
outcome indicated that in the V2 loop, the F176A, D180A,
I184A, and D185A mutations signiﬁcantly reduced the binding
aﬃnity of b12, which supports our ﬁnding in regard to the
contact sites identiﬁed in the V2 loop.50
The oxidation extents of residues M95 and W96 were
decreased by 41.9 and 71.3%, respectively, upon b12 binding
and are likely involved in the binding interface with b12 based
on the docking model of the crystal structure of b12 and the
CD4-complexed gp120 core structure of HXB2. However, the
previous observation that the M95A mutation causes a very
modest decrease in b12 binding aﬃnity for JR-CSF gp120 (75%
of WT binding) suggests that this residue, while protected by
the gp120−b12 interface, is probably not energetically involved
in stabilizing the binding to any signiﬁcant extent.7,50
Hydrogen−deuterium exchange (HDX) studies were pre-
viously reported for the KNH1144 SOSIP.664 trimer structure
bound to b12. These studies largely monitor changes in
secondary structure dynamics that alter backbone hydrogen
bonding stability, serving as complementary information for the
side chain-oriented HR-HRPF data presented here. HDX
protection proﬁles of the V1/V2 domain upon b12 binding
were complex, with some peptides showing a stabilized
secondary structure and others showing a destabilized
secondary structure, and with changes in stability diﬀering
over time. The fact that HDX data are usually limited in spatial
resolution to the peptide level further increases the diﬃculty in
interpreting the data. The V1/V2 region is clearly structurally
altered by b12 binding in complex ways, with the region of
residues ∼100−175 being destabilized by b12 binding and
residues 176−179 being slightly stabilized.53 Combined with
our HR-HRPF data, this suggests that HDX protection of this
region is largely limited to the area of direct contact with the
b12 antibody, with regions aﬀected conformationally by b12
binding in this region exhibiting increased HDX rates.
Figure 5. HR-HRPF and glycosylation of the V1/V2 and V3 domains.
Aligned model of full-length glycosylated gp120 after MD simulation
(light gray ribbon) bound to the b12 Fab (dark gray ribbon) (PDB
entry 2NY7). Residues that showed >80% protection from HR-HRPF
upon b12 binding are colored red. Residues that showed between 40
and 80% protection from HR-HRPF upon b12 binding are colored
orange. Residues that showed statistically signiﬁcant protection from
HR-HRPF of <40% are colored yellow. Residues showing no
protection from HR-HRPF upon b12 binding are colored blue. The
CDR loops of the light chain modeled to potentially interact with the
V1/V2 domain are shown. The inset shows the orientation of the
C157, F176, and Y173 side chains relative to the β-sheet.
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V3 Domain. The V3 domain is a highly ﬂexible loop that is
missing from the stabilized gp120−b12 crystal structure. The
V3 loop is heavily modiﬁed by HR-HRPF, suggesting a high
degree of solvent accessibility. The vast majority of residues in
the V3 domain (C296, K305−R313, D324, I325, R326, and
Q327) show no protection upon b12 binding, indicating that
the domain remains highly ﬂexible in the b12-bound form.
However, slight to moderate protection is observed for I322a
and I323. Via examination of the location of these residues in
the MD simulation of full-length glycosylated gp120 (Figure 5),
I322a and I323 are adjacent to Y173, an amino acid in the V1/
V2 domain that shows complete protection upon b12 binding.
We suggest that the b12-induced conformational change in the
V1/V2 domain allows for interaction between I322a and I323
and the V1/V2 domain, perhaps through Y173. While the
modest extent of protection of I322a and I323 suggests that this
interaction is not completely protecting, the protection is both
signiﬁcant and unique in the V3 domain. This suggests that
interactions between V3 and other molecules (e.g., heparan
sulfate54) could modulate the aﬃnity of the b12 antibody. This
observation is supported by the fact that the V3 domain of
KNH1144 SOSIP.664 shows a marked increase in HDX rates
upon b12 binding, and the V3 peptides most markedly aﬀected
are those containing residues 322 and 323,53 as well as by
mutational and recombinant analysis yielding evidence that the
V3 region interacts directly with the V1/V2 domain in DH102
gp120.55 Though the deletion of the V3 loop (residues N302−
D324) was reported to reduce the binding aﬃnity of b12, it is
currently unknown which particular residues mediate the
interaction.50
C1 and C5 Domains. Ten residues were observed as
oxidized in the C1 domain, four of which experience protection
upon b12 binding: M95, W96, M100, and M104. These
residues cluster at a loop and the N-terminal region of the large
central helix of the C1 domain. Alanine scanning mutagenesis
of binding of b12 to JR-CSF gp120 did not cover this end of
the helix thoroughly and did not directly test any of the
residues protected by HRPF; K97A caused a modest increase in
apparent aﬃnity, while E102A caused a modest decrease.
Mutagenesis at the C-terminal end of this helix showed an
almost complete loss of binding aﬃnity, suggesting a role for
the helix in the interaction.50 Hydrogen−deuterium exchange
of the KNH1144 SOSIP.664 trimer with b12 indicated this
region exhibits increased exchange rates upon antibody binding,
suggesting that antibody binding destabilizes the secondary
structure of the N-terminal end of the C1 helix.53 The HDX
data (which largely probe backbone secondary structure
stability) combined with our HR-HRPF data (which probe
side chain solvent accessibility) suggest that antibody binding
increases the amount of side chain packing not by stabilizing
the helical structure, but by destabilizing the helical structure
and granting the side chains additional ﬂexibility to maximize
interactions. In our model, the protected N-terminal end of the
C1 helix packs against a helix in the C5 domain that contains
the only protected residue in C5, M475 (Figure 6). Residues
G471−M475 show substantial contact with the heavy chain of
b12, with M475 showing a 29.5 Å2 interaction surface with the
b12 heavy chain.10 Mutagenesis data revealed that mutation of
M475 to alanine increased the apparent aﬃnity of b12 for JR-
CSF gp120 by a very modest amount, while mutation of the
nearby G473 to alanine increased aﬃnity almost 10-fold.
However, quadruple mutation of G473, D474, M475, and R476
to alanine increased the apparent relative aﬃnity for b12 only
2.5-fold, and GM and DMR multiple mutations increased the
apparent aﬃnity to an extent similar to that seen for the M475A
mutant alone, suggesting that the large eﬀect of G473A may be
due to stabilization of the helix, with the interactions mediated
by the amino acids in the helix.50 On the basis of our data and
the glycosylated homology model, the binding of the b12 heavy
chain ﬁxes the C5 domain helix by direct contact, shielding
M475. The binding simultaneously destabilizes the backbone of
the N-terminus of the C1 helix as shown by HDX,53 with the
destabilized helix packing against the ﬁxed C5 helix, providing
the observed shielding of M95, W96, M100, and M104.
Residues in domains C1 and C5 that are not protected (F53,
C54, H66, H72, and C74 in domain C1 and L494 and K500 in
the C-terminal tail of domain C5) are distal to this interaction
interface and do not experience any direct contact or signiﬁcant
stabilization by b12 binding, showed no change in HDX
experiments,53 and were not in the covered regions of the
previously reported alanine mutagenesis work.50
C4 Domain. The C4 domain contains three sites that
exhibited modest protection upon b12 binding (P417-C418-
R419, M434, and Y435) as well as one highly reactive cysteine
that showed modest exposure upon b12 binding (C445). The
P417-C418-R419 region interacts directly with W100 from
CDR H3 of the b12 antibody (Figure 7A). While the P417-
C418-R419 region was not analyzed by alanine mutagenesis,
W100 of b12 was shown to be essential for b12 binding,51 as
was K421 of JR-CSF gp120;50 this interaction explains the
protection observed here.
The slight observed protection of M434 and Y435 and the
modest exposure observed by C445 are more diﬃcult to
understand. This region does not appear to directly interact
Figure 6. HR-HRPF protection suggests stabilization of the helix α1−
helix α5 interaction upon binding of b12 to helix α5. Helix α1 of the
C1 domain (green) shows protection of four residues: M95 and W96
in the loop at the N-terminus of helix α1 and M99 and M104 within
helix α1. The sole residue probed in helix α5, M475, interacts directly
with a CDR loop of the b12 heavy chain (dark gray), with helix α5
(light gray) packing against the N-terminus of helix α1. Residues that
showed >80% protection from HR-HRPF upon b12 binding are
colored red. Residues that showed between 40 and 80% protection
from HR-HRPF upon b12 binding are colored orange. Residues that
showed statistically signiﬁcant protection from HR-HRPF of <40% are
colored yellow. Residues showing no protection from HR-HRPF upon
b12 binding are colored blue.
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with b12 in our MD model or in the crystal structure. This
region shows considerable ﬂexibility in the MD simulations of
free gp120 as the C-terminal end of the β-strand of residues
413−426, as well as the entire β-strand of residues 432−436,
completely unravels, deviating signiﬁcantly from the crystal
structure of the stabilized gp120−b12 complex (Figure 7B).
Upon b12 binding, M434 and Y435 in the small β-strand show
protection, suggesting this β-strand may be stabilized by b12
binding. This hypothesis is supported by HDX analysis of
KNH1144 SOSIP.664 bound to b12, where binding shows
slight protection of peptide 427−433 and very little change in
peptide 435−445,53 indicating that the protection is largely
occurring in residues associated with this strand. However,
M426 at the extreme C-terminal end of the β-strand of residues
413−426 shows no protection yet shows considerable ﬂexibility
in the MD simulation of free gp120 as the C-terminal of its β-
strand unravels. C445 in the C4 domain exhibits modest
exposure upon b12 binding but shows little deviation between
the MD simulation of free gp120 and the X-ray crystal structure
of the stabilized gp120−b12 complex, remaining in a β-strand
conﬁguration. While HDX analysis suggests no signiﬁcant
change in the secondary structure stability at C44553 and our
MD simulation indicates that the displacement of this residue
in the strand is small, b12 binding does result in statistically
signiﬁcant exposure of C445. Of note, previous HR-HRPF
results have indicated that cysteine oxidation is sensitive to
relatively small changes in solvent accessibility;31 it is probable
that the modest exposure observed in C445 indicates a small
change in the average solvent accessibility of this residue.
Previous alanine scanning mutagenesis data support the
importance of this region to b12 binding: mutations K421A
and M426A resulted in large losses of binding aﬃnity of b12 for
JR-CSF gp120, while mutation N425A resulted in a very slight
loss of aﬃnity. Similarly, mutation K432A (the only mutated
residue in the strand of residues 432−436) resulted in a large
loss of aﬃnity. Interestingly, the V430A mutant in the turn
between these two strands showed a >5-fold increase in
apparent aﬃnity,50 suggesting the reduced bulk of the alanine
residue in this turn improves the interaction eﬃciency, perhaps
by improving stabilization of these two β-strands. On the basis
of these data and the MD simulation, we hypothesize that b12
binding stabilizes the C-terminus of the strand of residues 413−
426 and the paired 432−436 strand, but the extreme C-
terminal end of the strand of residues 413−426 in the stabilized
crystal structure remains suﬃciently disordered to not register
topographical protection in HR-HRPF. The β-strand starting
with C445 appears to undergo a slight displacement upon b12
binding by MD simulation, which we can detect only because
of the sensitivity of cysteine residues to SASA changes in HR-
HRPF.
C3 Domain. Seven residues in the C3 domain were
oxidized. Three residues at the edges of the folded domain
(C331, F353, and C377) experienced no protection upon b12
binding. These residues mostly exist in loops between
secondary structure elements, and these loops are distal to
the b12 interaction elements; a lack of protection of these
residues upon b12 binding would be anticipated.
Four residues experience strong protection upon b12
binding. Three of these residues cluster around glysocylation
site N362: V360, F361, and H363. The Man9GlcNAc2 glycan
modeled on the N362 site is poised to interact with the b12
light chain (Figure 8). On the basis of the glycosylated gp120
model and our HR-HRPF data, it appears that the interaction
of the N362 glycan with the light chain of b12 protects the
region around N362. Examination of the CATNAP database56
suggests that an intact glycosylation sequon at N362 is not
correlated with b12 binding across various gp120 sequences,
suggesting that while interaction with b12 may stabilize the
Figure 7. b12 both interacts directly with domain C4 and alters its dynamics. Residues that showed >80% protection from HR-HRPF upon b12
binding are colored red. Residues that showed between 40 and 80% protection from HR-HRPF upon b12 binding are colored orange. Residues that
showed statistically signiﬁcant protection from HR-HRPF of <40% are colored yellow. Residues showing no protection from HR-HRPF upon b12
binding are colored blue. Residue C445 (also blue) showed an increase in the level of oxidation upon b12 binding. (A) P417, C418, and R419 of
strand β19 (orange ribbon and licorice) interact directly with W100 (dark gray ribbon and licorice) of the CDR H3 loop of the b12 heavy chain,
which extends out from the bulk of the b12 IgG fold. (B) Model of full-length, glycosylated gp120 (light gray) aligned with the crystal structure of
stabilized, b12-bound gp120 (dark gray), with only the C4 domain backbone shown for the sake of clarity and the b12 antibody shown as a space-
ﬁlling model. Strand β22/β23 remains largely unperturbed; however, strands β20 and β21 are much more ﬂexible in the full-length, glycosylated,
unbound gp120 MD simulation. HR-HRPF data of M426 show no protection upon b12 binding, suggesting that there is no appreciable change in
the conformation or dynamics of this residue in strand β20. However, the protection of M434 and Y435 suggests that strand β21 does experience a
stabilization upon b12 binding.
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topography around this glycosylation site, the interaction is not
energetically important for b12 binding.
W338 in the C3 domain shows complete protection from
HR-HRPF upon b12 binding. W338 exists at the N-terminal
end of the large α2 helix of the C3 domain. This helix does not
interact with b12 in either the X-ray crystal structure or the full-
length glycosylated model. W338 is directly adjacent to the
N339 glycosylation site. However, in our model, the N339
Man9GlcNAc2 glycan does not directly interact with the b12
antibody. It is possible that b12 binding triggers conformational
changes in the core of the C3 domain or in the C3−C4
domain−domain interactions (namely, between helix α2 of the
C3 domain and strand β22/β23 of the C4 domain) that are
observed in the strong HR-HRPF protection of W338
observed. Mutagenesis of the K343 residue in helix α2 and
T450 in the center of strand β22/β23 showed a greatly
decreased aﬃnity for the b12 antibody,50 supporting a potential
impact of b12 binding on this region.
It is also possible that the N339 glycan is involved in
interactions that are not properly captured by our model.
Interestingly, the CATNAP database56 shows a strong positive
correlation between an intact N339 glycosylation sequon and
b12 binding, suggesting that glycosylation of N339 is involved,
directly or indirectly, in the energetics of b12 binding. Previous
deglycosylation studies by Koch and co-workers did not
examine elimination of the N339 or N362 glycosylation
site.18 While it is not apparent how the N339 glycan could
interact directly with the b12 antibody, perhaps the N339
glycan contributes indirectly via another glycan, which interacts
directly with b12.
Unprotected Domains. The C2 and V4 domains both had
at least one residue probed by HR-HRPF, but no residues that
showed protection upon b12 binding. For the C2 domain, eight
residues were probed by HR-HRPF (C205, C218, C239, S274,
D275, F277, L288, and K289), including three cysteines that
are highly sensitive to changes in solvent accessibility. This
domain is distal to the b12 antibody binding interface and
largely consists of ﬂexible loops and small antiparallel β-sheets.
All of the HR-HRPF-probed residues are found on regions
lacking secondary structure in both the MD model and the X-
ray crystal structure of the stabilized gp120−b12 complex,
indicating that the binding of b12 does not appreciably change
the structure or dynamics of the loops. The residues in the β-
sheets were silent in this HR-HRPF experiment. Interestingly,
several residues in the C2 domain were found by mutagenesis
to aﬀect b12 binding aﬃnity, mostly among residues that are
conserved among most gp120 sequences.50 Unfortunately, in
no case did we receive HR-HRPF data directly on a residue
mutated by Pantophlet and co-workers, and the pattern of
mutations that changed binding aﬃnity is by no means clear;
several of the mutations that decreased b12 binding aﬃnity
occurred on the stretch of residues 223−239 of the C2 domain
that was unoxidized by HR-HRPF (Figure 2).
The V4 domain had one residue at its extreme C-terminus
probed by HR-HRPF, I414, which can be seen near the N-
terminal end of strand β19 in Figure 7A. The interaction with
b12 occurs at the C-terminal end of the long β19 strand, and
the lack of HR-HRPF protection of I414 upon b12 binding
suggests that the N-terminal end of this strand remains stable in
the absence of b12 binding. No mutagenesis data for this
residue have been reported, and CATNAP database analysis
showed no correlation between this amino acid identity and
b12 aﬃnity.
■ CONCLUSION
We demonstrate the ability of the hydroxyl radical-mediated
protein footprinting combined with molecular modeling to
examine the protein−protein interactions between a highly
glycosylated mature gp120 and its bNAb b12. The data
presented here identiﬁed the highly occupied glycosylation sites
and probed the solvent accessibility of 61 residues in full-length,
glycosylated JR-FL gp120 and identiﬁed 23 residues protected
upon b12 binding. Analysis of our results in the context of a
model of full-length, glycosylated gp120 indicates a prominent
role of interactions of the V1/V2 domain with the light chain of
the b12 antibody, as well as potential roles for the N362 glycan
in interacting directly with b12. HR-HRPF was able to detect
both direct interactions and conformational changes upon b12
binding without the need to introduce mutations or site-speciﬁc
chemical labels that could alter the native conformation we seek
to probe. The combination of HR-HRPF for providing
biophysical data on the full-length glycosylated gp120 protein
and molecular modeling for providing a context to interpret
changes in HR-HRPF protection is powerful. Further studies
examining the interactions of gp120 with other bNAbs are
underway.
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